Table 1.
Demographics for patients surviving more than 1 year after HCT.
| UCB | MRD/MUD | All Patients | ||
|---|---|---|---|---|
| N=102 | N=354 | N=456 | P-Value | |
| (22.40%) | (77.60%) | (100%) | ||
| Age | ||||
| Median (IQR) | 42 (33 – 51) | 49.5 (39 – 58) | 48 (38 – 57) | <0.001 |
| Donor Age | ||||
| Median (IQR) | – | 50 (41–57) | – | – |
| Gender | ||||
| M | 58 (56.9%) | 201 (56.8%) | 259 (56.8%) | 0.99 |
| Race | ||||
| White | 72 (70.6%) | 328 (92.7%) | 400 (87.7%) | <0.001 |
| Black | 25 (24.5%) | 22 (6.2%) | 47 (10.3%) | |
| Asian | 5 (4.9%) | 2 (0.6%) | 7 (1.5%) | |
| American Indian | 0 (0%) | 2 (0.6%) | 2 (0.4%) | |
| Ethnicity | ||||
| Not Hispanic | 96 (94.1%) | 343 (96.9%) | 439 (96.3%) | 0.22 |
| Hispanic | 5 (4.9%) | 7 (2%) | 12 (2.6%) | |
| Unknown | 1 (1%) | 4 (1.1%) | 5 (1.1%) | |
| Pre-HCT BMI | ||||
| Median (IQR) | 27.84 (24.28 – 31.77) | 27.62 (24.25 – 30.96) | 27.63 (24.25 – 31.11) | 0.47 |
| Disease | ||||
| Acute Leukemia | 71 (69.6%) | 174 (49.2%) | 245 (53.7%) | 0.001 |
| MDS/MPN | 7 (6.9%) | 70 (19.8%) | 77 (16.9%) | |
| Lymphoma | 13 (12.7%) | 61 (17.2%) | 74 (16.2%) | |
| Chronic Leukemia | 11 (10.8%) | 49 (13.8%) | 60 (13.2%) | |
| Status at Transplant | ||||
| Complete Remission | 80 (78.4%) | 204 (57.6%) | 284 (62.3%) | 0.0004 |
| Partial Response | 12 (11.8%) | 50 (14.1%) | 62 (13.6%) | |
| Progressive Disease | 4 (3.9%) | 45 (12.7%) | 49 (10.7%) | |
| Stable Disease | 6 (5.9%) | 55 (15.5%) | 61 (13.4%) | |
| Time from diagnosis to HCT | ||||
| Median (IQR) | 390.5 (196–677) | 363.5 (159–872) | 364.5 (166.5–807.5) | 0.22 |
| Decade of HCT | ||||
| 1996–2005 | 24 (23.5%) | 69 (19.5%) | 93 (20.4%) | 0.40 |
| 2006–2015 | 78 (76.5%) | 285 (80.5%) | 363 (79.6%) | |
| TBI | ||||
| n (%) | 85 (83.3%) | 102 (28.8%) | 187 (41%) | <0.001 |
| Conditioning | ||||
| Myeloablative | 62 (60.8%) | 180 (50.8%) | 242 (53.1%) | 0.08 |
| Cell source | ||||
| UCB | 102 (100%) | – | 102 (22.4%) | – |
| Peripheral blood | – | 329 (92.9%) | 329 (72.1%) | |
| Bone marrow | – | 25 (7.1%) | 25 (5.5%) | |
| KPS | ||||
| 80–100 | 89 (87.3%) | 290 (81.9%) | 379 (83.1%) | 0.008 |
| ≤70 | 11 (10.8%) | 64 (18.1%) | 75 (16.4%) | |
| Unknown | 2 (2%) | 0 (0%) | 2 (0.4%) | |
| Time to neutrophil engraftment | ||||
| Median (IQR) | 21.5 (15 – 27) | 16.5 (14 – 20) | 17 (14 – 21) | <.0001 |
| Time to platelet engraftment | ||||
| Median (IQR) | 41 (33 – 52) | 16 (13 – 21) | 19 (14 – 28) | <.0001 |
| Graft failure | ||||
| Y | 12 (11.8%) | 5 (1.4%) | 17 (3.7%) | <.0001 |
| N | 90 (88.2%) | 349 (98.6%) | 439 (96.3%) | |
| Relapse | ||||
| Y | 19 (18.6%) | 86 (24.3%) | 105 (23%) | 0.23 |
| N | 83 (81.4%) | 268 (75.7%) | 351 (77%) | |
| Time to Relapse | ||||
| Median (IQR) | 421 (265 – 1100) | 310.5 (169 – 539) | 342 (189 – 575) | 0.006 |
| aGVHD | ||||
| Y | 65 (63.7%) | 197 (55.6%) | 262 (57.5%) | 0.03 |
| N | 20 (19.6%) | 117 (33.1%) | 137 (30%) | |
| Unknown | 16 (15.7%) | 40 (11.3%) | 56 (12.3%) | |
| aGVHD grade | ||||
| <2 or Unknown | 56 (54.9%) | 224 (63.3%) | 280 (61.4%) | 0.13 |
| ≥2 | 46 (45.1%) | 130 (36.7%) | 176 (38.6%) | |
| cGVHD | ||||
| Y | 31 (30.4%) | 116 (32.8%) | 147 (32.2%) | 0.72 |
| N | 71 (69.6%) | 238 (67.2%) | 309 (67.8%) | |
| cGVHD grade | ||||
| Mild or Unknown | 95 (93.1%) | 289 (81.6%) | 384 (84.2%) | 0.005 |
| Moderate or Severe | 7 (6.9%) | 65 (18.4%) | 72 (15.8%) | |
| HCT-CI | ||||
| ≤3 | 38 (61.3%) | 188 (73.7%) | 226 (71.3%) | 0.052 |
| >3 | 24 (38.7%) | 67 (26.3%) | 91 (28.7%) | |
| HCT before 12/2007 | 40 | 99 | 139 | |
| DRI | ||||
| Low | 20 (19.6%) | 81 (22.9%) | 101 (22.1%) | 0.81 |
| Int | 70 (68.6%) | 222 (62.7%) | 292 (64%) | |
| High | 9 (8.8%) | 38 (10.7%) | 47 (10.3%) | |
| Very High | 3 (2.9%) | 13 (3.7%) | 16 (3.5%) | |